Abstract
Children are at increased risk for influenza and its complications, so including them in vaccine trials is critical. Researchers have now conducted a manufacturer-funded, multinational, phase III, observer-blinded trial of a novel inactivated quadrivalent influenza vaccine (QIV) in children aged 3 to 8 years. About 5200 children were randomly assigned to receive either the QIV vaccine (which contains both B lineages …
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call